When contemplating return of pain or withdrawal on account of adverse events as lack of response (LTR), therapy with LYRICA resulted in a longer time to loss of therapeutic response than treatment with placebo. Fifty-3 % from the pregabalin-handled topics as compared to 33% of placebo individuals remained on analyze drug and managed a therapeutic r